Safety, Effectiveness, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

• Status: RECRUITING
• Trial end date: 2030-12-01

Summary

This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC).

This study includes two substudies (substudy A and substudy B) that will recruit participants according to histological subtypes due to differences in chemotherapy choice for standard-of-care and type of NSCLC.

• Phase: PHASE2

Details

• Lead Sponsor: BioNTech SE
• Collaborator: Biotheus Inc.
• Treatments: Carboplatin; Paclitaxel; pembrolizumab; Pemetrexed